133 related articles for article (PubMed ID: 35608445)
21. A Prospective Study on
Rousseau E; Wilson D; Lacroix-Poisson F; Krauze A; Chi K; Gleave M; McKenzie M; Tyldesley S; Goldenberg SL; Bénard F
J Nucl Med; 2019 Nov; 60(11):1587-1593. PubMed ID: 30979820
[No Abstract] [Full Text] [Related]
22. Patterns of Prostate Cancer Recurrence After Brachytherapy Determined by Prostate-Specific Membrane Antigen-Positron Emission Tomography and Computed Tomography Imaging.
Raman S; Keyes M; Oh J; Rousseau E; Krauze A; Wilson D; Bénard F
Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1126-1134. PubMed ID: 34986383
[TBL] [Abstract][Full Text] [Related]
23. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.
Hofman MS; Lawrentschuk N; Francis RJ; Tang C; Vela I; Thomas P; Rutherford N; Martin JM; Frydenberg M; Shakher R; Wong LM; Taubman K; Ting Lee S; Hsiao E; Roach P; Nottage M; Kirkwood I; Hayne D; Link E; Marusic P; Matera A; Herschtal A; Iravani A; Hicks RJ; Williams S; Murphy DG;
Lancet; 2020 Apr; 395(10231):1208-1216. PubMed ID: 32209449
[TBL] [Abstract][Full Text] [Related]
24. Incremental Impact of [
Szigeti F; Schweighofer-Zwink G; Meissnitzer M; Hauser-Kronberger C; Hitzl W; Kunit T; Forstner R; Pirich C; Beheshti M
Mol Imaging Biol; 2022 Feb; 24(1):50-59. PubMed ID: 34519966
[TBL] [Abstract][Full Text] [Related]
25.
Mena E; Lindenberg ML; Turkbey IB; Shih JH; Harmon SA; Lim I; Lin F; Adler S; Eclarinal P; McKinney YL; Citrin D; Dahut W; Wood BJ; Krishnasamy V; Chang R; Levy E; Merino M; Pinto P; Eary JF; Choyke PL
J Nucl Med; 2020 Jun; 61(6):881-889. PubMed ID: 31676732
[TBL] [Abstract][Full Text] [Related]
26. Utility of
Galgano SJ; McDonald AM; Rais-Bahrami S; Porter KK; Choudhary G; Burgan C; Bhambhvani P; Nix JW; Morgan DE; Li Y; Thomas JV; McConathy J
AJR Am J Roentgenol; 2021 Sep; 217(3):720-729. PubMed ID: 33052718
[No Abstract] [Full Text] [Related]
27. Clinical impact of PSMA PET/CT in primary prostate cancer compared to conventional nodal and distant staging: a retrospective single center study.
Donswijk ML; van Leeuwen PJ; Vegt E; Cheung Z; Heijmink SWTPJ; van der Poel HG; Stokkel MPM
BMC Cancer; 2020 Aug; 20(1):723. PubMed ID: 32758168
[TBL] [Abstract][Full Text] [Related]
28. Repeatability of Quantitative
Jansen BHE; Cysouw MCF; Vis AN; van Moorselaar RJA; Voortman J; Bodar YJL; Schober PR; Hendrikse NH; Hoekstra OS; Boellaard R; Oprea-Lager DE
J Nucl Med; 2020 Sep; 61(9):1320-1325. PubMed ID: 31924729
[TBL] [Abstract][Full Text] [Related]
29. The Impact of
Parikh NR; Tsai S; Bennett C; Lewis M; Sadeghi A; Lorentz W; Cheung M; Garraway I; Aronson W; Kishan AU; Bahri S; Vahidi K; Calais J; Ishimitsu D; Rettig M; Nickols NG; Jafari L
Adv Radiat Oncol; 2020; 5(6):1364-1369. PubMed ID: 33305100
[TBL] [Abstract][Full Text] [Related]
30. Comparison between
Liu Y; Dong Y; Liu J; Zhang X; Lin M; Xu B
Prostate; 2021 Dec; 81(16):1329-1336. PubMed ID: 34516670
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic and therapeutic impact of PET/CT with 18F-DCFPyL versus 18F-Fluorocholine in initial staging of intermediate-/high-risk prostate cancer: a pilot study.
Lucas Lucas C; García Zoghby L; Amo-Salas M; Soriano Castrejón ÁM; García Vicente AM
Ann Nucl Med; 2023 Oct; 37(10):551-560. PubMed ID: 37532975
[TBL] [Abstract][Full Text] [Related]
32.
Ortega C; Schaefferkoetter J; Veit-Haibach P; Anconina R; Berlin A; Perlis N; Metser U
J Nucl Med; 2020 Nov; 61(11):1615-1620. PubMed ID: 32198311
[TBL] [Abstract][Full Text] [Related]
33. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.
Chen Y; Pullambhatla M; Foss CA; Byun Y; Nimmagadda S; Senthamizhchelvan S; Sgouros G; Mease RC; Pomper MG
Clin Cancer Res; 2011 Dec; 17(24):7645-53. PubMed ID: 22042970
[TBL] [Abstract][Full Text] [Related]
34. Comparison between conventional imaging (abdominal-pelvic computed tomography and bone scan) and [(18)F]choline positron emission tomography/computed tomography imaging for the initial staging of patients with intermediate- tohigh-risk prostate cancer: A retrospective analysis.
Evangelista L; Cimitan M; Zattoni F; Guttilla A; Zattoni F; Saladini G
Scand J Urol; 2015; 49(5):345-53. PubMed ID: 25649494
[TBL] [Abstract][Full Text] [Related]
35. Prostate cancer recurrence in patients with negative or equivocal conventional imaging: A role for
Kim EH; Siegel BA; Teoh EJ; Andriole GL;
Urol Oncol; 2021 Jun; 39(6):365.e9-365.e16. PubMed ID: 33160848
[TBL] [Abstract][Full Text] [Related]
36. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.
Poulsen MH; Bouchelouche K; Høilund-Carlsen PF; Petersen H; Gerke O; Steffansen SI; Marcussen N; Svolgaard N; Vach W; Geertsen U; Walter S
BJU Int; 2012 Dec; 110(11):1666-71. PubMed ID: 22520686
[TBL] [Abstract][Full Text] [Related]
37. Simplified Methods for Quantification of
Jansen BHE; Yaqub M; Voortman J; Cysouw MCF; Windhorst AD; Schuit RC; Kramer GM; van den Eertwegh AJM; Schwarte LA; Hendrikse NH; Vis AN; van Moorselaar RJA; Hoekstra OS; Boellaard R; Oprea-Lager DE
J Nucl Med; 2019 Dec; 60(12):1730-1735. PubMed ID: 31000583
[TBL] [Abstract][Full Text] [Related]
38. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
[TBL] [Abstract][Full Text] [Related]
39.
Wondergem M; van der Zant FM; Knol RJJ; Burgers AMG; Bos SD; de Jong IJ; Pruim J
World J Urol; 2018 Jan; 36(1):27-34. PubMed ID: 29043431
[TBL] [Abstract][Full Text] [Related]
40. A Comparison of
Fourquet A; Rosenberg A; Mena E; Shih JJ; Turkbey B; Blain M; Bergvall E; Lin F; Adler S; Lim I; Madan RA; Karzai F; Gulley JL; Dahut WL; Wood BJ; Chang R; Levy E; Choyke PL; Lindenberg L
J Nucl Med; 2022 May; 63(5):735-741. PubMed ID: 34475237
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
